Advertisement
AMGN vs BMY
Which Stock Would AI Choose? Amgen (AMGN) vs. Bristol-Myers Squibb (BMY) Stock Comparison
Key Takeaways
- Both AMGN and BMY are large-cap biopharmaceutical companies gearing up for Q1 2026 earnings reports on April 30, with analysts projecting revenue growth for AMGN and a slight EPS dip for BMY.
- BMY has shown stronger year-to-date performance at 9.5% versus AMGN's 4.65%, reflecting resilient momentum in recent market activity.
- AMGN boasts a larger market cap of $183 billion and a forward P/E ratio (price-to-earnings ratio) of 15.22, compared to BMY's $118 billion cap and 9.20 forward P/E.
- Analyst consensus leans moderately positive for both, with average price targets implying ~4% upside for AMGN to $353 and ~9% for BMY to $63.
- BMY offers a higher dividend yield of 4.36%, appealing to income-focused investors, while AMGN emphasizes growth through pipeline advancements.
Introduction
This stock comparison examines AMGN and BMY, two leading biopharmaceutical firms known for their oncology portfolios and innovative therapies. Investors and traders analyzing the healthcare sector may find value in contrasting their recent market positioning, valuation metrics, and growth trajectories. Amid broader market volatility and anticipation for upcoming earnings, this analysis highlights relative performance, risk profiles, and sentiment drivers to inform strategic decision-making in a competitive biotech landscape.
AMGN Overview and Recent Performance
Amgen Inc. (AMGN) is a biotechnology pioneer specializing in human therapeutics, with key products in inflammation, oncology, and cardiovascular areas. Trading around $340 per share with a market cap exceeding $183 billion, the stock has delivered modest year-to-date gains of 4.65% within a 52-week range of $261 to $391. Recent weeks have seen some downward pressure amid broader market rises, influenced by news such as a proposed FDA withdrawal of its drug Tavneos and an AI-focused leadership reshuffle. Sentiment remains supported by strong analyst coverage, with an overweight consensus and average target of $353, ahead of Q1 earnings on April 30 where EPS of $4.77 is anticipated. Lower beta of 0.47 underscores its relative stability.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) develops treatments in immunology, oncology, and hematology, bolstered by its past merger with Celgene. At approximately $58 per share and a $118 billion market cap, BMY has outperformed year-to-date with 9.5% returns in a 52-week range of $43 to $63. Recent market activity reflects mixed drug portfolio dynamics and challenges from generics and debt, contributing to short-term declines despite higher trading volume. Analyst targets average $63, signaling potential upside, as Q1 earnings loom on April 30 with expected revenue of $10.92 billion but a 20% EPS drop to $1.44. Its low beta of 0.27 and 4.36% dividend yield attract defensive investors.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available models that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies, including technical and fundamental analysis, across timeframes like 5-minute to 60-minute charts and volatility levels from low to high. Key stats displayed include win rates, profit factors, and Sharpe ratios (a measure of risk-adjusted returns), helping users identify bots suited to current market conditions. Virtual agents, signal agents, and brokerage agents offer varied styles for short-term trading or longer holds. Traders can filter by asset class or performance to deploy automated strategies efficiently. Explore Trending AI Robots for tools tailored to today’s dynamic markets.
Head-to-Head Comparison
Both AMGN and BMY operate R&D-intensive business models in biopharma, but AMGN emphasizes biotech innovation with broader pipeline catalysts like Repatha expansions, while BMY balances diversified revenue amid patent expirations. Growth drivers differ: AMGN benefits from acquisition integrations and AI initiatives, contrasting BMY's focus on immunology stability. Recent momentum favors BMY YTD, but AMGN shows superior long-term trend consistency. Risk factors include regulatory hurdles for AMGN and generics/debt pressures for BMY, with BMY's lower beta offering less volatility. Sector exposure is similar in oncology, yet market sentiment tilts toward AMGN for growth potential versus BMY's value appeal.
Tickeron AI Verdict
Tickeron’s AI currently leans toward AMGN in this matchup, driven by its larger scale, favorable forward growth estimates, and analyst overweight consensus amid pipeline catalysts. While BMY offers compelling value through lower forward P/E and higher yield, AMGN's relative stability and momentum position it probabilistically stronger for near-term outperformance, particularly post-earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and BMY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- BMY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 5 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 3 bearish.
- BMY’s TA Score: 5 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +1.61% price change this week, while BMY (@Pharmaceuticals: Major) price change was -0.24% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +4.69%.
Reported Earning Dates
AMGN is expected to report earnings on Jul 30, 2026.
BMY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | BMY | AMGN / BMY | |
| Capitalization | 192B | 117B | 164% |
| EBITDA | 16.7B | 15B | 111% |
| Gain YTD | 10.098 | 8.271 | 122% |
| P/E Ratio | 24.72 | 16.00 | 154% |
| Revenue | 37.2B | 48.5B | 77% |
| Total Cash | 12B | 10.5B | 114% |
| Total Debt | 57.3B | 46.4B | 123% |
AMGN | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 24 | 91 | |
SMR RATING 1..100 | 12 | 25 | |
PRICE GROWTH RATING 1..100 | 48 | 50 | |
P/E GROWTH RATING 1..100 | 60 | 68 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (6) in the Biotechnology industry is in the same range as BMY (19) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.
AMGN's Profit vs Risk Rating (24) in the Biotechnology industry is significantly better than the same rating for BMY (91) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than BMY’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is in the same range as BMY (25) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.
AMGN's Price Growth Rating (48) in the Biotechnology industry is in the same range as BMY (50) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.
AMGN's P/E Growth Rating (60) in the Biotechnology industry is in the same range as BMY (68) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to BMY’s over the last 12 months.
| AMGN | BMY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 52% |
| Stochastic ODDS (%) | 2 days ago 41% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 62% | 2 days ago 46% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 55% |
| Advances ODDS (%) | 2 days ago 56% | 2 days ago 54% |
| Declines ODDS (%) | 4 days ago 51% | 12 days ago 54% |
| BollingerBands ODDS (%) | 2 days ago 50% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 54% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.40% | ||
| PFE - BMY | 59% Loosely correlated | +0.15% | ||
| AMGN - BMY | 57% Loosely correlated | +0.32% | ||
| NVS - BMY | 55% Loosely correlated | -0.55% | ||
| GSK - BMY | 53% Loosely correlated | +0.34% | ||
| ABBV - BMY | 52% Loosely correlated | +1.32% | ||
More | ||||